CA2709915C - New polypeptides having affinity for her2 - Google Patents

New polypeptides having affinity for her2 Download PDF

Info

Publication number
CA2709915C
CA2709915C CA2709915A CA2709915A CA2709915C CA 2709915 C CA2709915 C CA 2709915C CA 2709915 A CA2709915 A CA 2709915A CA 2709915 A CA2709915 A CA 2709915A CA 2709915 C CA2709915 C CA 2709915C
Authority
CA
Canada
Prior art keywords
cancer
her2
polypeptide according
radionuclide
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2709915A
Other languages
English (en)
French (fr)
Other versions
CA2709915A1 (en
Inventor
Lars Abrahmsen
Nina Herne
Joachim Feldwisch
Christofer Lendel
Vladimir Tolmachev
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Affibody AB
Original Assignee
Affibody AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affibody AB filed Critical Affibody AB
Publication of CA2709915A1 publication Critical patent/CA2709915A1/en
Application granted granted Critical
Publication of CA2709915C publication Critical patent/CA2709915C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA2709915A 2007-12-21 2008-12-22 New polypeptides having affinity for her2 Active CA2709915C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP07150395.7 2007-12-21
EP07150395A EP2072525A1 (en) 2007-12-21 2007-12-21 New polypeptides having affinity for HER2
PCT/EP2008/068167 WO2009080810A1 (en) 2007-12-21 2008-12-22 New polypeptides having affinity for her2

Publications (2)

Publication Number Publication Date
CA2709915A1 CA2709915A1 (en) 2009-07-02
CA2709915C true CA2709915C (en) 2016-05-24

Family

ID=39148791

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709915A Active CA2709915C (en) 2007-12-21 2008-12-22 New polypeptides having affinity for her2

Country Status (11)

Country Link
US (2) US8501909B2 (https=)
EP (2) EP2072525A1 (https=)
JP (2) JP5913807B2 (https=)
CN (2) CN101952302B (https=)
AU (1) AU2008339976B2 (https=)
CA (1) CA2709915C (https=)
DK (1) DK2235044T3 (https=)
ES (1) ES2440919T3 (https=)
HK (1) HK1202880A1 (https=)
PL (1) PL2235044T3 (https=)
WO (1) WO2009080810A1 (https=)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
US9187535B2 (en) 2007-12-19 2015-11-17 Affibody Ab Polypeptide derived from protein A and able to bind PDGF
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2
AU2009282413B2 (en) 2008-08-11 2014-07-17 Nektar Therapeutics Multi-arm polymeric alkanoate conjugates
US20120165650A1 (en) 2010-12-22 2012-06-28 General Electric Company Her2 binders
WO2010120514A2 (en) 2009-03-31 2010-10-21 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2496598B1 (en) 2009-11-04 2017-08-02 Affibody AB Her3 binding polypeptides
CA2789738C (en) * 2010-03-08 2021-03-09 Ge Healthcare Bio-Sciences Ab Immunoglobulin g fc region binding polypeptide
DE102010026061A1 (de) 2010-06-30 2012-01-05 Siemens Aktiengesellschaft 11C-markiertes Peptid zur Detektion eines Tumors, der einen Her2/neu-Rezeptor exprimiert
TWI486617B (zh) * 2010-10-21 2015-06-01 Iner Aec Executive Yuan 一種測定對鎝（Ｔｃ－９９ｍ）與錸（Ｒｅ－１８６、Ｒｅ－１８８）具有穩定錯合力之含硫螯合劑在凍晶劑中之含量與均一性的固態樣品分析技術
WO2012088422A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
WO2012088445A1 (en) 2010-12-22 2012-06-28 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
NZ612161A (en) * 2010-12-22 2015-04-24 Gen Electric Radiolabled her2 binding peptides
US9061080B2 (en) 2010-12-22 2015-06-23 Ge Healthcare Limited HER2 binding peptides labeled with aluminium-[18] fluoride complexed by NOTA
RU2013128360A (ru) * 2010-12-22 2015-01-27 ДжиИ ХЕЛТКЕР ЛИМИТЕД Her2-связывающие белки, меченые 18f-содержащим кремнийорганическим соединением
CN102690345B (zh) * 2011-03-24 2014-03-19 江苏靶标生物医药研究所有限公司 人膜联蛋白v变体及其表达、制备和应用
US20140088021A1 (en) 2011-05-27 2014-03-27 Nektar Therapeutics Water-Soluble Polymer-Linked Binding Moiety and Drug Compounds
EP3511339B1 (en) 2012-02-20 2025-04-09 IPC Research, LLC Polypeptides binding to human complement c5
WO2014013016A1 (en) 2012-07-20 2014-01-23 Affibody Ab Method for determining the her2 status of a malignancy
JP6440618B2 (ja) * 2012-10-05 2018-12-19 アフィボディ・アーベー Ｈｅｒ３結合ポリペプチド
WO2014076179A1 (en) 2012-11-14 2014-05-22 Affibody Ab New polypeptide
KR20160055728A (ko) * 2013-06-27 2016-05-18 지이 헬쓰케어 리미티드 Her2 결합제의 용도
BR112016003142A2 (pt) 2013-08-28 2017-10-17 Swedish Orphan Biovitrum Ab Publ ligação de polipeptídeos estáveis ao c5 do complemento humano
MX367423B (es) 2013-08-28 2019-08-21 Affibody Ab Polipeptidos de union a c5.
JP6935195B2 (ja) 2014-03-11 2021-09-15 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. 結合領域、志賀毒素ａサブユニットのエフェクター領域、及びカルボキシ末端小胞体局在化シグナルモチーフを含むタンパク質
ES2809729T3 (es) 2014-03-11 2021-03-05 Molecular Templates Inc Proteínas que comprenden regiones efectoras de la subunidad A de la toxina Shiga próximas al extremo amino terminal y regiones de unión de tipo inmunoglobulina de reconocimiento celular capaces de unirse específicamente a HER2/neu/ErbB2
CN104292308B (zh) * 2014-08-22 2017-09-15 广州安辰医药科技有限公司 肿瘤抗原环肽
CA2964958A1 (en) 2014-10-31 2016-05-06 The Trustees Of The University Of Pennsylvania Methods and compositions for modified t cells
CA2969067A1 (en) * 2014-11-25 2016-06-02 Bristol-Myers Squibb Company Novel pd-l1 binding polypeptides for imaging
CN107207379B (zh) 2014-11-25 2021-08-10 百时美施贵宝公司 用于生物制品的18f-放射性标记的方法和组合物
EP3303373B1 (en) 2015-05-30 2020-04-08 Molecular Templates, Inc. De-immunized, shiga toxin a subunit scaffolds and cell-targeting molecules comprising the same
KR20180030085A (ko) 2015-07-26 2018-03-21 몰레큘러 템플레이츠, 인코퍼레이션. 시가 독소 a 서브유닛 작동체 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
US10994033B2 (en) 2016-06-01 2021-05-04 Bristol-Myers Squibb Company Imaging methods using 18F-radiolabeled biologics
JP7016323B2 (ja) 2016-06-01 2022-02-21 ブリストル－マイヤーズ スクイブ カンパニー Ｐｄ－ｌ１結合ポリペプチドを用いるｐｅｔ造影
MX2019008840A (es) 2017-01-25 2019-09-09 Molecular Templates Inc Moleculas con direccion hacia las celulas que comprenden efectores de la sub-unidad a de la toxina shiga desinmunizados y epitopos de las celulas t cd8+.
CN110612117B (zh) 2018-04-17 2024-04-12 分子模板公司 包含去免疫化的志贺毒素a亚基支架的her2靶向分子
EP4077368A1 (en) 2019-12-18 2022-10-26 Bracco Imaging SPA Anti-her2 polypeptides derivatives as new diagnostic molecular probes
WO2021122726A1 (en) 2019-12-18 2021-06-24 Bracco Imaging Spa Anti-her2 polypeptides derivatives as new diagnostic molecular probes
CN112220931B (zh) * 2020-10-16 2022-03-08 上海交通大学 用于肿瘤主动靶向治疗的亲和体-细胞毒素偶联物及其纳米颗粒、制备方法、应用
EP4291251B1 (en) * 2021-02-15 2025-02-19 Affibody AB Her2-binding polypeptide
CN112999369B (zh) * 2021-03-03 2022-02-25 江苏元本生物科技有限公司 一种her2亲合体放射性核素标记物组合物及其应用
CN116063397B (zh) * 2022-07-04 2025-05-02 中国药科大学 一类靶向her2蛋白的多肽及其在制备多肽偶联药物中的应用
CN117430670A (zh) * 2022-07-20 2024-01-23 中国科学院上海药物研究所 一种her2靶向肽分子及其应用
TW202416938A (zh) 2022-08-10 2024-05-01 日商興和股份有限公司 親和體微胞(affibody micelle)藥物複合體
TW202545983A (zh) 2024-01-25 2025-12-01 瑞典商艾菲博迪公司 新穎多肽

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE509359C2 (sv) 1989-08-01 1999-01-18 Cemu Bioteknik Ab Användning av stabiliserade protein- eller peptidkonjugat för framställning av ett läkemedel
US5650489A (en) 1990-07-02 1997-07-22 The Arizona Board Of Regents Random bio-oligomer library, a method of synthesis thereof, and a method of use thereof
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
CA2531238C (en) * 2003-07-04 2015-02-24 Affibody Ab Polypeptides having binding affinity for her2
SE0301987D0 (sv) * 2003-07-04 2003-07-04 Affibody Ab New polypeptide
GB0524788D0 (en) * 2005-12-05 2006-01-11 Affibody Ab Polypeptides
US8124725B2 (en) * 2007-12-19 2012-02-28 General Electric Company PDGF-Rβ binders
US8937047B2 (en) 2007-12-19 2015-01-20 General Electric Company Biokinetics of fast-clearing polypeptides
EP2077272A1 (en) 2007-12-21 2009-07-08 Affibody AB Polypeptide libraries with a predetermined scaffold
ES2373832T3 (es) 2007-12-19 2012-02-09 Affibody Ab Polipéptido derivado de proteína a y capaz de unirse a pdgf.
EP2072525A1 (en) * 2007-12-21 2009-06-24 Affibody AB New polypeptides having affinity for HER2

Also Published As

Publication number Publication date
JP2011507497A (ja) 2011-03-10
JP2015061838A (ja) 2015-04-02
US8501909B2 (en) 2013-08-06
CN101952302A (zh) 2011-01-19
HK1153207A1 (en) 2012-03-23
CN101952302B (zh) 2014-11-12
JP5913807B2 (ja) 2016-04-27
EP2235044A1 (en) 2010-10-06
EP2072525A1 (en) 2009-06-24
EP2235044B1 (en) 2013-10-09
US20130280164A1 (en) 2013-10-24
CA2709915A1 (en) 2009-07-02
HK1202880A1 (en) 2015-10-09
PL2235044T3 (pl) 2014-03-31
US20110020223A1 (en) 2011-01-27
ES2440919T3 (es) 2014-01-31
CN104327179A (zh) 2015-02-04
DK2235044T3 (da) 2014-01-06
US8883120B2 (en) 2014-11-11
AU2008339976A1 (en) 2009-07-02
WO2009080810A1 (en) 2009-07-02
AU2008339976B2 (en) 2013-05-30

Similar Documents

Publication Publication Date Title
CA2709915C (en) New polypeptides having affinity for her2
CA2531238C (en) Polypeptides having binding affinity for her2
MX2013000314A (es) Polipeptidos.
Honarvar et al. Evaluation of backbone-cyclized HER2-binding 2-helix Affibody molecule for In Vivo molecular imaging
CN1816563B (zh) 对her2具有结合亲和力的多肽
Ekblad et al. Positioning of 99mTc-chelators influences radiolabeling, stability and biodistribution of Affibody molecules
US20240124533A1 (en) New her2-binding polypeptide
HK1153207B (en) New polypeptides having affinity for her2
WO2024181930A1 (en) Asparaginyl peptide ligase-mediated radiolabelling of single-domain antibodies
WO2025158010A1 (en) Her2-binding polypeptide
KR20260007574A (ko) 신규 폴리펩티드
HK1092481B (en) Polypeptides having binding affinity for her2

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131209

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 16TH ANNIV.) - STANDARD

Year of fee payment: 16

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241210

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241210

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 17TH ANNIV.) - STANDARD

Year of fee payment: 17

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251120

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251120